Mauna Kea Technologies Secures NMPA Approval for Cellvizio Gen 3 Platform in China

Reuters11-21

<a href="https://laohu8.com/S/MKEAF">Mauna Kea Technologies</a> Secures NMPA Approval for Cellvizio Gen 3 Platform in China

Mauna Kea Technologies SA has received regulatory approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio® Gen 3 platform. This approval, valid for five years until November 2030, permits the use of the Gen 3 system with the company's full range of confocal probes in China. The certification process was completed independently by Mauna Kea Technologies and is not part of its previous joint venture with Tasly. The company is now evaluating commercialization options to bring the advanced platform to Chinese hospitals. No grant or funding from multiple organizations was announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120016496) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585564691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 00:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585564691","market":"us","top_or_hot":-1,"title":"Mauna Kea Technologies Secures NMPA Approval for Cellvizio Gen 3 Platform in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKEAF\">Mauna Kea Technologies</a> Secures NMPA Approval for Cellvizio Gen 3 Platform in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mauna Kea Technologies SA has received regulatory approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio® Gen 3 platform. This approval, valid for five years until November 2030, permits the use of the Gen 3 system with the company's full range of confocal probes in China. The certification process was completed independently by Mauna Kea Technologies and is not part of its previous joint venture with Tasly. The company is now evaluating commercialization options to bring the advanced platform to Chinese hospitals. No grant or funding from multiple organizations was announced.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120016496) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mauna Kea Technologies Secures NMPA Approval for Cellvizio Gen 3 Platform in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMauna Kea Technologies Secures NMPA Approval for Cellvizio Gen 3 Platform in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 00:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKEAF\">Mauna Kea Technologies</a> Secures NMPA Approval for Cellvizio Gen 3 Platform in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mauna Kea Technologies SA has received regulatory approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio® Gen 3 platform. This approval, valid for five years until November 2030, permits the use of the Gen 3 system with the company's full range of confocal probes in China. The certification process was completed independently by Mauna Kea Technologies and is not part of its previous joint venture with Tasly. The company is now evaluating commercialization options to bring the advanced platform to Chinese hospitals. No grant or funding from multiple organizations was announced.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120016496) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL2ZlDwK:1","article_id":"2585564691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585564691","pubTimestamp":1763657115,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mauna Kea Technologies SA has received regulatory approval from the National Medical Products Administration  in China for the import and commercialization of its next-generation Cellvizio Gen 3 platform. This approval, valid for five years until November 2030, permits the use of the Gen 3 system with the company's full range of confocal probes in China. The certification process was completed independently by Mauna Kea Technologies and is not part of its previous joint venture with Tasly. The company is now evaluating commercialization options to bring the advanced platform to Chinese hospitals. No grant or funding from multiple organizations was announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA publi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600535":"天士力","BK0239":"医药制造","BK0028":"国家队","BK1191":"制药","BK1570":"华润系","BK0012":"证金概念","BK0196":"行业龙头","03320":"华润医药","BK0188":"融资融券","BK0183":"MSCI概念"},"translate_title":"Mauna Kea Technologies CellVizio Gen 3平台在中国获得NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600535":0.9,"03320":0.9},"content_text":"Mauna Kea Technologies Secures NMPA Approval for Cellvizio Gen 3 Platform in China\n    \n\n        Mauna Kea Technologies SA has received regulatory approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio® Gen 3 platform. This approval, valid for five years until November 2030, permits the use of the Gen 3 system with the company's full range of confocal probes in China. The certification process was completed independently by Mauna Kea Technologies and is not part of its previous joint venture with Tasly. The company is now evaluating commercialization options to bring the advanced platform to Chinese hospitals. No grant or funding from multiple organizations was announced.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120016496) on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585564691","isCrawlerRequest":true}